Frequency of HbA1c discordance in estimating blood glucose control

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 4, 2008, Pages 512-517

  Cohen, Robert M ^a   Smith, Eric P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Complications; Glycation; Glycation gap; Glycemic control; HbA1c; Red cell lifespan

Indexed keywords

FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

AFFINITY CHROMATOGRAPHY; ANION EXCHANGE; BLOOD GLUCOSE MONITORING; DIABETES CONTROL; ENVIRONMENTAL FACTOR; ERYTHROCYTE LIFESPAN; EXTRACELLULAR SPACE; FREQUENCY ANALYSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOLOGY; HEMOGLOBIN DETERMINATION; HEREDITY; HUMAN; IMMUNOASSAY; INTRACELLULAR SPACE; MICROANGIOPATHY; PHYSIOLOGY; PREDICTION; PROTEIN GLYCOSYLATION; REVIEW; BLOOD; DIABETES MELLITUS; GLYCOSYLATION; METABOLISM; PREDICTION AND FORECASTING; RISK FACTOR;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; FRUCTOSAMINE; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 54049105337     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32830467bd     Document Type: Review

References (61)

1. Jeha GS, Haymond M. Understanding and interpreting laboratory test results in the clinical management of diabetes mellitus. Pediatr Endocrinol Rev 2007; 5 (Suppl 1):608-628.
2. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310:341-346.
3. Goodall I. HbA1c standardisation destination: global IFCC Standardisation. How, why, where and when: a tortuous pathway from kit manufacturers, via inter-laboratory lyophilized and whole blood comparisons to designated national comparison schemes. Clin Biochem Rev 2005; 26:5-19.
4. Bunn HF. Nonenzymatic glycosylation of protein: relevance to diabetes. Am J Med 1981; 70:325-330.
5. Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications 2002; 16:313-320.
6. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in nondiabetic subjects not related to glycaemia. Clin Chim Acta 1997; 260:49-64.
7. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004; 27:1259-1264.
8. Cohen RM. A1C: does one size fit all? Diabetes Care 2007; 30:2756-2758.
9. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 2003; 26:163-167.
10. Cohen RM, Snieder H, Lindsell CJ, et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 2006; 29:1739-1743.
11. Chalew SA, McCarter RJ, Thomas J, et al. A comparison of the glycosylation gap and hemoglobin glycation index in patients with diabetes. J Diabetes Complications 2005; 19:218-222.
12. Higgins TN. QA aspects for HbA1c measurements. Clin Biochem 2008; 41:88-90.
13. Cohen RM, LeCaire TJ, Lindsell CJ, et al. The relationship of prospective glycated hemoglobin to glycated serum proteins in incident diabetic retinopathy: implications of the glycation gap for mechanism of risk prediction. Diabetes Care 2008; 31:151-153.
14. Wilson D, Fiallo-Scharer R, Xing D, et al. Diabetes Research in Children Network: Reliability of two indices of the biologic variability in glycosylation among children and adolescents with T1DM. [abstract]. Diabetes 2005; 54.
15. Kim J-I, Stevens RJ, Holman RR. The haemoglobin glycation index is an independent risk factor for microvascular complications in UKPDS patients with newly diagnosed type 2 diabetes [abstract]. Diabetes 2005; 54.
16. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the diabetes control and complications trial. Diabetes 2007; 56:1913-1921.
17. Herman WH, Ma Y, Uwaifo G, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30:2453-2457. This is a particularly important study that strongly supports the notion that there are either racial or ethnic differences or both in HbA1c not explained by differences in glycemic control. If proven to be correct, this has major implications for HbA1c interpretation.
18. Berlin NI, Waldmann TA, Weissman SM. Life span of red blood cell. Physiol Rev 1959; 39:577-616.
19. Panzer S, Kronik G, Lechner K, et al. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood 1982; 59:1348-1350.
20. Cohen RM, Ciraolo P, Palascak MB, et al. Red blood cell (RBC) survival differences among hematologically normal people with diabetes (DM) make a clinically important difference in HbA1c. [abstract]. Diabetes 2007; 56:A116.
21. Lindsell CJ, Franco RS, Smith EP, et al. A method for the continuous calculation of the age of labeled red blood cells. Am J Hematol 2008 [Epub ahead of print]
22. Strocchi A, Schwartz S, Ellefson M, et al. A simple carbon monoxide breath test to estimate erythrocyte turnover. J Lab Clin Med 1992; 120:392-399.
23. Virtue MA, Furne JK, Nuttall FQ, Levitt MD. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 2004; 27:931-935.
24. Bunn HF, Haney DN, Kamin S, et al. The biosynthesis of human hemoglobin A1 c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976; 57:1652-1659.
25. Smith RJ, Koenig RJ, Binnerts A, et al. Regulation of hemoglobin AIc formation in human erythrocytes in vitro. Effects of physiologic factors other than glucose. J Clin Invest 1982; 69:1164-1168.
26. Khera PK, Joiner CH, Holmes YR, Cohen RM. Evidence for a steady state glucose gradient across the erythrocyte membrane at 37C: a potential source of variation in hemoglobin A1c. [abstract]. Diabetes 2001; 50:A176.
27. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun 1969; 36:838-843.
28. Szwergold BS, Howell SK, Beisswenger PJ. Transglycation-a potential new mechanism for deglycation of Schiffs bases. Ann N Y Acad Sci 2005; 1043:845-864.
29. Szwergold BS. Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases. Biochem Biophys Res Commun 2005; 336:36-41.
30. Freedman BI, Hicks PJ, Sale MM, et al. A leucine repeat in the carnosinase geneCNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant 2007; 22:1131-1135.
31. Sauerhofer S, Yuan G, Braun GS, et al. L-carnosine, a substrate of carno-sinase-1, influences glucose metabolism. Diabetes 2007; 56:2425-2432.
32. Szwergold BS, Howell S, Beisswenger PJ. Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 2001; 50:2139-2147.
33. Szwergold BS, Beisswenger PJ. Enzymatic deglycation-a new paradigm or an epiphenomenon? Biochem Soc Trans 2003; 31:1428-1432.
34. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007; 30:2399-2400.
35. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007; 50:2239-2244.
36. Sharp P, Rainbow S. Continuous glucose monitoring and haemoglobin A(1c). Ann Clin Biochem 2002; 39:516-517.
37. Salardi S, Zucchini S, Santoni R, et al. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA(lc) in pediatric type 1 diabetic patients. Diabetes Care 2002; 25:1840-1844.
38. Hassan Y, Johnson B, Nader N, et al. The relationship between 24-h integrated glucose concentrations and % glycohemoglobin. J Lab Clin Med 2006; 147:21-26.
39. Service FJ. Correlation between glycemia and glycated hemoglobin. Compr Ther 1990; 16:33-40.
40. Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem 2007; 53:897-901.
41. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44:968-983.
42. Mosca IF, Goodall I, Hoshino T, et al. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med 2007; 45:1077-1080.
43. Nuttall FQ. Comparison of percentage total GHb with percentage HbA1c in people with and without known diabetes. Diabetes Care 1998; 21:1475-1480.
44. Nuttall FQ. Total glycohemoglobin or hemoglobin A1C? Endocr Pract 2007; 13:317-318.
45. Iguchi K, Nakanishi T, Miyazaki A, et al. Development of an isotope dilution mass spectrometry assay for HbA1c based on enzyme-cleaved peptide analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 806:25-31.
46. Nordin G, Dybkaer R. Recommendation for term and measurement unit for 'HbA1c'. Clin Chem Lab Med 2007; 45:1081-1082.
47. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.
48. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-986.
49. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117.
50. Genuth S, Eastman R, Kahn R, et al. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003; 26 (Suppl 1):S28-S32.
51. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
52. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macro-vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
53. Beisswenger PJ, Howell SK, O'Dell RM, et al. alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001; 24:726-732.
54. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295:1681-1687.
55. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006; 295:1707-1708.
56. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29:1486-1490.
57. Service FJ, O'Brien PC. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007; 30: 1 86-1 88.
58. Hirsch IB, Brownlee M. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007; 30:186-187.
59. Monnier L, Colette C, Leiter L, et al. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007; 30:185-186.
60. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; CD006063.
61. Nathan DM. Rosiglitazone and cardiotoxicity-weighing the evidence. N Engl J Med 2007; 357:64-66.